ANT3310 + meropenem

ANT3310 + meropenem is a combination antibacterial therapy consisting of **ANT3310**, an investigational broad-spectrum serine-beta-lactamase (SBL) inhibitor, and **meropenem**, a well-established carbapenem antibiotic. ANT3310 is designed to restore and expand the efficacy of meropenem by inhibiting a wide range of beta-lactamases—including OXA and KPC-type carbapenemases—produced by multidrug-resistant (MDR) Gram-negative bacteria such as *Acinetobacter baumannii*, carbapenem-resistant Enterobacterales (CRE), and *Pseudomonas aeruginosa*. The combination provides enhanced coverage against hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), complicated urinary tract infections (cUTI), and complicated intra-abdominal infections (cIAI). ANT3310 functions by irreversibly binding and inhibiting serine-beta-lactamases, while meropenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. ANT3310 + meropenem has completed Phase 1 clinical trials, with promising safety, pharmacokinetic compatibility, and broad-spectrum antibacterial activity against highly resistant pathogens[1][3][5][7].

Brand names

MEM-ANT3310MEM-ANT-3310MEM-ANT 3310

Other names

MEM-ANT3310MEM-ANT-3310MEM-ANT 3310